Beijing Mabworks Biotech Co., Ltd.

This study is testing whether a new antibody treatment called MIL62 can help control systemic lupus erythematosus, a serious autoimmune disease. About 316 adults with active lupus will receive either MIL62 or a placebo injection over 52 weeks to see if it reduces disease activity…

This early-stage study aims to test the safety and effects of a new drug called MIL116, which is an antibody designed to target a protein involved in IgA nephropathy. It will first be given to healthy volunteers to check for safety, and then to patients with the kidney disease to…